Medicine Press release

Eisai Co., Ltd. announced today that it has been listed in the 2025 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Biologics License Application (BLA) for lecanemab-irmb (U.S. brand name: LEQEMBI) subcutaneous autoinjector (SC-AI) for weekly maintenance dosing.
More info..

A collaborative research group led by Professor Kenjiro Ono of the Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, and Eisai Co., Ltd.
More info..

Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announced that it has been selected for inclusion in the 2024 Dow Jones Sustainability World Index (DJSI World), one of the most globally recognized corporate sustainability indices. Olympus has now been named to the DJSI World for four consecutive years. Olympus has also been named to the 2024 Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific) for six.
More info..

Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announced that it has been selected for inclusion in the 2024 Dow Jones Sustainability World Index (DJSI World), one of the most globally recognized corporate sustainability indices. Olympus has now been named to the DJSI World for four consecutive years. Olympus has also been named to the 2024 Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific) for six.
More info..

Fujirebio Holdings, Inc., a wholly-owned subsidiary of H.U. Group Holdings, Inc., and Eisai Co., Ltd. announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases.
More info..

NEC Bio Therapeutics today presents 24-week promising interim results from an ongoing Phase 1 basket clinical trial of an orally administered cancer vaccine, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPI) for treating patients with solid tumors.
More info..

Eisai Co., Ltd. announced today that it has received approval for "URECE(R)" (generic name: dotinurad) from the National Medical Products Administration in China as a treatment for gout patients with hyperuricemia.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (AD).
More info..

Honda Research Institute Japan Co., Ltd. (HRI-JP), a Honda R&D subsidiary responsible for the research of cutting-edge technologies, has officially introduced its AI-powered social robot named "Haru" at the Virgen del Rocio University Hospital (HUVR) in Seville, Spain, to enhance the well-being of children while in the hospital.
More info..